| Drug Name |
Ticagrelor |
| Drug ID |
BADD_D02214 |
| Description |
Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y12 receptor antagonism.[A2903] Unlike [clopidogrel], ticagrelor is not a prodrug.[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207].
Ticagrelor was granted EMA approval on 3 December 2010.[L14207]
Ticagrelor was granted FDA approval on 20 July 2011.[L14201] |
| Indications and Usage |
For the prevention of thrombotic events (for example stroke or heart attack) in patients with acute coronary syndrome or myocardial infarction with ST elevation. |
| Marketing Status |
Prescription |
| ATC Code |
B01AC24 |
| DrugBank ID |
DB08816
|
| KEGG ID |
D09017
|
| MeSH ID |
D000077486
|
| PubChem ID |
9871419
|
| TTD Drug ID |
D0WF7L
|
| NDC Product Code |
62147-0280; 69238-1134; 50923-0314; 15894-0030; 17228-7777; 58623-0131; 69037-0007; 45941-3055; 50379-0023; 55154-9618; 55111-969; 46708-883; 49587-109; 17228-0777; 50379-0011; 0186-0777; 17228-0776; 49187-0205; 76072-1016; 0186-0776; 65372-1198 |
| Synonyms |
Ticagrelor | Brilique | AZD 6140 | AZD6140 | AZD-6140 | Brilinta | 3-(7-((2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-(1-3)-triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
